Ligand Pharmaceuticals reported $608.23M in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Agenus USD 78.81M 16.47M Jun/2026
Amgen USD 34.36B 598M Sep/2026
Anika Therapeutics USD 99.19M 5.63M Jun/2026
Arrowhead Research USD 1.29B 382.19M Sep/2026
Baxter International USD 6.83B 163M Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Eli Lilly USD 65.26B 591M Sep/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Enviri Corporation USD 722.11M 1.43M Mar/2026
Gilead Sciences USD 16.55B 4.02B Sep/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
Glaxosmithkline GBP 17.9B 134M Sep/2026
Heron Therapeutics USD 209.11M 20.73M Sep/2026
Insmed USD 1.71B 72.59M Sep/2026
Intrexon USD 23.72M 45.04M Jun/2024
Ionis Pharmaceuticals USD 2.36B 129.77M Sep/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Ligand Pharmaceuticals USD 608.23M 848.88M Sep/2026
MacroGenics USD 295.08M 26.61M Sep/2026
Merck USD 38.94B 2.26B Sep/2026
Pacira USD 10.3B 9.68B Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Veracyte USD 467.88M 106.9M Sep/2026